Markets

Akebia Therapeutics (AKBA) in Focus: Stock Moves Up 13%

Akebia Therapeutics, Inc.AKBA was a big mover last session, as its shares rose over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Yesterday's rally continues the recent uptrend for the company, as the stock is now up nearly 40% in the past one-month time frame.

Over the last 30 days, the company did not witness any estimate revision while the Zacks Consensus Estimate moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts.

Akebia Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

A better-ranked med-drugs stock is Auris Medical Holding AG EARS with a Zacks Rank #1 (Strong Buy).

Is AKBA going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AKEBIA THERAP (AKBA): Free Stock Analysis Report

AURIS MEDICAL (EARS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EARS AKBA

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More